Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial have?
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial has 41 citations in the OpenAlex counts ScholarIQ stores.
When was Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial published?
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial has 2024 year in the ScholarIQ index.
What is the open-access status of Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial?
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial has closed oa status in the ScholarIQ index.
What is the DOI of Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial?
The DOI for Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial is on the source record.
What is the PMID of Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial?
The PMID for Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial is on the source record.
What is the OpenAlex record for Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial?
The OpenAlex for Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial is on the source record.